Journal Article

Octyl Methoxycinnamate Modulates Gene Expression and Prevents Cyclobutane Pyrimidine Dimer Formation but not Oxidative DNA Damage in UV-Exposed Human Cell Lines

Nur Duale, Ann-Karin Olsen, Terje Christensen, Shamas T. Butt and Gunnar Brunborg

in Toxicological Sciences

Volume 114, issue 2, pages 272-284
Published in print April 2010 | ISSN: 1096-6080
Published online January 2010 | e-ISSN: 1096-0929 | DOI:

More Like This

Show all results sharing these subjects:

  • Medical Toxicology
  • Toxicology (Non-medical)


Show Summary Details


Octyl methoxycinnamate (OMC) is one of the most widely used sunscreen ingredients. To analyze biological effects of OMC, an in vitro approach was used implying ultraviolet (UV) exposure of two human cell lines, a primary skin fibroblast (GM00498) and a breast cancer (MCF-7) cell lines. End points include cell viability assessment, assay of cyclobutane pyrimidine dimers (CPDs) and oxidated DNA lesions using alkaline elution and lesion-specific enzymes, and gene expression analysis of a panel of 17 DNA damage–responsive genes. We observed that OMC provided protection against CPDs, and the degree of protection correlated with the OMC-mediated reduction in UV dose. No such protection was found with respect to oxidative DNA lesions. Upon UV exposure in the presence of OMC, the gene expression studies showed significant differential changes in some of the genes studied and the expression of p53 protein was also changed. For some genes, the change in expression seemed to be delayed in time by OMC. The experimental approach applied in this study, using a panel of 17 genes in an in vitro cellular system together with genotoxicity assays, may be useful in the initial screening of active ingredients in sunscreens.

Keywords: octyl methoxycinnamate; cyclobutane pyrimidine dimers; oxidative DNA lesions; UV; sunscreens; gene expression

Journal Article.  6669 words.  Illustrated.

Subjects: Medical Toxicology ; Toxicology (Non-medical)

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.